Update on tumours of the adrenal cortex, phaeochromocytoma and extra-adrenal paraganglioma

Histopathology

Volumn 58, Issue 2, 2011, Pages 155-168

  McNicol, Anne Marie ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adenoma; Adrenal gland; Carcinoma; Paragangliomas; Phaeochromocytoma

Indexed keywords

BETA CATENIN; CYCLIN D1; INHIBIN; KI 67 ANTIGEN; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAS PROTEIN; SOMATOMEDIN B; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE B; SUCCINATE DEHYDROGENASE C; SUCCINATE DEHYDROGENASE D; UNCLASSIFIED DRUG; WNT PROTEIN;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CAROTID BODY TUMOR; CHEMODECTOMA; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MITOSIS RATE; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

ADRENAL GLAND NEOPLASMS; HUMANS; PARAGANGLIOMA, EXTRA-ADRENAL; PHEOCHROMOCYTOMA;

EID: 79951638361     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03613.x     Document Type: Review

References (175)

1. Dobbie JW, Symington T. The human adrenal gland with special reference to the vasculature. J. Endocrinol. 1966; 34; 479-489.
2. Wong DL. Epinephrine biosynthesis: hormonal and neural control during stress. Cell. Mol. Neurobiol. 2006; 26; 891-900.
3. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin. Endocrinol. (Oxf.) 2007; 66; 607-618.
4. Reinhard C, Saeger W, Schubert B. Adrenocortical nodules in post-mortem series. Development, functional significance, and differentiation from adenomas. Gen. Diagn. Pathol. 1996; 141; 203-208.
5. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med. 2007; 356; 601-610.
6. Bovio S, Cataldi A, Reimondo G et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 2006; 29; 298-302.
7. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr. Rev. 1995; 16; 460-483.
8. Beuschlein F, Reincke M. Adrenocortical tumorigenesis. Ann. N.Y. Acad. Sci. 2006; 1088; 319-334.
9. Dobbie JW. Adrenocortical nodular hyperplasia. The ageing adrenal. J. Pathol. 1969; 99; 1-18.
10. Spain DM, Weinsaft P. Solitary adrenal cortical adenoma in elderly female; frequency. Arch. Pathol. 1964; 78; 231-233.
11. Beuschlein F, Reincke M, Karl M et al. Clonal composition of human adrenocortical neoplasms. Cancer Res. 1994; 54; 4927-4932.
12. Gicquel C, Leblond-Francillard M, Bertagna X et al. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin. Endocrinol. (Oxf) 1994; 40; 465-477.
13. Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R, Galera H, Wolfe HJ. Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex. Am. J. Pathol. 2000; 156; 311-319.
14. Favre L, Jacot-des-Combes E, Morel P et al. Primary aldosteronism with bilateral adrenal adenomas. Virchows Arch. A (Pathol. Anat.) 1980; 388; 229-236.
15. Desai N, Kapoor A, Singh BK, Liu J. Bilateral adrenal adenomas and persistent leukocytosis: a unique case of Cushing's syndrome. Am. J. Med. 2006; 119; e3-e5.
16. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia, 3rd Series edn. Washington, DC: Armed Forces Institute of Pathology, 1997.
17. Brennan MF. Adrenocortical carcinoma. CA-A Cancer J. Clin. 1987; 37; 348-353.
18. Correa P, Chen VW. Endocrine gland cancer. Cancer 1995; 75; 338-352.
19. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973; 223; 1109-1112.
20. Hutter AMJ, Kayhoe DE. Adrenal cortical carcinoma. Am. J. Med. 1966; 41; 572-580.
21. Ibanez ML. The pathology of adrenal cortical carcinomas. Study of 22 cases. Endocrine and nonendocrine hormone-producing tumors. Chicago: Year Book Medical Publishers, 1971; 231-239.
22. MacFarlane DA. Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases. Ann. R. Coll. Surg. Engl. 1958; 23; 155-186.
23. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996; 119; 161-170.
24. Paton BL, Novitsky YW, Zerey M et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006; 140; 914-920; discussion 919-920.
25. Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981; 47; 2153-2161.
26. Huvos AG, Hajdu SI, Brasfield RD, Foote F. Adrenal cortical carcinoma. Cancer 1970; 25; 354-361.
27. King DR, Lack EE. Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer 1979; 44; 239-244.
28. Schulick RD, Brennan MF. Adrenocortical carcinoma. World J. Urol. 1999; 17; 26-34.
29. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol. 2003; 169; 5-11.
30. Zografos GC, Driscoll DL, Karakousis CP, Huben RP. Adrenal adenocarcinoma: a review of 53 cases. J. Surg. Oncol. 1994; 55; 160-164.
31. Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumours. Am. J. Clin. Pathol. 1979; 72; 390-399.
32. Lack EE, Travis WD, Oertel JE. Adrenal cortical neoplasms. In Lack EE ed. Pathology of the adrenal glands. New York: Churchill Livingstone, 1990; 115-171.
33. Van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985; 55; 766-773.
34. Weiss LM. Comparable histologic study of 43 metastasizing and non metastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984; 8; 163-169.
35. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 1989; 13; 202-206.
36. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum. Pathol. 2009; 40; 757-768.
37. Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 2002; 26; 1612-1619.
38. van't Sant HP, Bouvy ND, Kazemier G et al. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology 2007; 51; 239-245.
39. Volante M, Bollito E, Sperone P et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 2009; 55; 535-543.
40. Arola J, Salmenkivi K, Liu J, Kahri AI, Heikkila P. p53 and Ki67 in adrenocortical tumors. Endocr. Res. 2000; 26; 861-865.
41. McNicol AM, Struthers AJ, Nolan CE, Hermans J, Haak HR. Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 status. Endocr. Pathol. 1997; 8; 29-36.
42. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod. Pathol. 1995; 8; 11-17.
43. McNicol AM, Nolan CE, Struthers AJ, Farquharson MA, Hermans J, Haak HR. Expression of p53 in adrenocortical tumours: clinicopathological correlations. J. Pathol. 1997; 181; 146-152.
44. Soon PS, Gill AJ, Benn DE et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr. Relat. Cancer 2009; 16; 573-583.
45. Schmitt A, Saremaslani P, Schmid S et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006; 49; 298-307.
46. Sredni ST, Alves VA, Latorre Mdo R, Zerbini MC. Adrenocortical tumours in children and adults: a study of pathological and proliferation features. Pathology 2003; 35; 130-135.
47. Sasano H, Suzuki T, Sano T, Kameya T, Sasano N, Nagura H. Adrenocortical oncocytoma. A true nonfunctioning adrenocortical tumor. Am. J. Surg. Pathol. 1991; 15; 949-956.
48. Xiao GQ, Pertsemlidis DS, Unger PD. Functioning adrenocortical oncocytoma: a case report and review of the literature. Ann. Diagn. Pathol. 2005; 9; 295-297.
49. Golkowski F, Buziak-Bereza M, Huszno B et al. The unique case of adrenocortical malignant and functioning oncocytic tumour. Exp. Clin. Endocrinol. Diabetes 2007; 115; 401-404.
50. Bisceglia M, Ludovico O, Di Mattia A et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int. J. Surg. Pathol. 2004; 12; 231-243.
51. Sobin LH, Wittekind C eds. TNM classification of malignant tumours. New York: Wiley-Liss, 2002.
52. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J. Urol. 1978; 120; 660-665.
53. Fassnacht M, Johanssen S, Quinkler M et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115; 243-250.
54. Lughezzani G, Sun M, Perrotte P et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur. J. Cancer 2010; 46; 713-719.
55. Morimoto R, Satoh F, Murakami O et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr. J. 2008; 55; 49-55.
56. Terzolo M, Boccuzzi A, Bovio S et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 2001; 57; 176-182.
57. McCluggage WG, Burton J, Maxwell P, Sloan JM. Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin. J. Clin. Pathol. 1998; 51; 114-116.
58. Munro LM, Kennedy A, McNicol AM. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J. Endocrinol. 1999; 161; 341-347.
59. Ghorab Z, Jorda M, Ganjei P, Nadji M. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl. Immunohistochem. Mol. Morphol. 2003; 11; 330-333.
60. Pan CC, Chen PC, Tsay SH, Ho DM. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl. Immunohistochem. Mol. Morphol. 2005; 13; 347-352.
61. Zhang H, Bu H, Chen H et al. Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors. Appl. Immunohistochem. Mol. Morphol. 2008; 16; 32-39.
62. Shibata H, Kobayashi S, Kurihara I, Saito I, Saruta T. Nuclear receptors and co-regulators in adrenal tumors. Horm. Res. 2003; 59(Suppl. 1); 85-93.
63. Sasano H, Shizawa S, Suzuki T et al. Ad4BP in the human adrenal cortex and its disorders. J. Clin. Endocrinol. Metab. 1995; 80; 2378-2380.
64. Sasano H. Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocr. J. 1994; 41; 471-482.
65. Haak HR, Fleuren GJ. Neuroendocrine differentiation of adrenocortical tumors. Cancer 1995; 75; 860-864.
66. Komminoth P, Roth J, Schroder S, Saremaslani P, Heitz PU. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors. Lab. Invest. 1995; 72; 424-431.
67. Soon PS, Sidhu SB. Molecular basis of adrenocortical carcinomas. Minerva Endocrinol. 2009; 34; 137-147.
68. Giordano TJ, Kuick R, Else T et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 2009; 15; 668-676.
69. Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008; 13; 548-561.
70. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr. Relat. Cancer 2007; 14; 13-28.
71. Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur. J. Endocrinol. 2005; 153; 477-487.
72. Sidhu S, Gicquel C, Bambach CP et al. Clinical and molecular aspects of adrenocortical tumourigenesis. Aust. NZ J. Surg. 2003; 73; 727-738.
73. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomarkers Prev. 2001; 10; 83-87.
74. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr. Dev. Pathol. 2005; 8; 287-304.
75. Roos A, Groen EJ, van Beek AP. Cushing's syndrome due to unilateral multiple adrenal adenomas as an extraintestinal manifestation of familial adenomatous polyposis. Int. J. Colorectal Dis. 2009; 24; 239.
76. Wakatsuki S, Sasano H, Matsui T, Nagashima K, Toyota T, Horii A. Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features. Hum. Pathol. 1998; 29; 302-306.
77. Machens A, Schaaf L, Karges W et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin. Endocrinol. (Oxf) 2007; 67; 613-622.
78. Langer P, Cupisti K, Bartsch DK et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J. Surg. 2002; 26; 891-896.
79. Sidhu S, Marsh DJ, Theodosopoulos G et al. Comparative genomic hybridization analysis of adrenocortical tumors. J. Clin. Endocrinol. Metab. 2002; 87; 3467-3474.
80. Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001; 61; 6762-6767.
81. Russell AJ, Sibbald J, Haak H, Keith WN, McNicol AM. Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. Br. J. Cancer 1999; 81; 684-689.
82. Kjellman M, Roshani L, Teh BT et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J. Clin. Endocrinol. Metab. 1999; 84; 730-735.
83. Reincke M, Mora P, Beuschlein F, Arlt W, Chrousos GP, Allolio B. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 1997; 82; 3054-3058.
84. Libe R, Groussin L, Tissier F et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin. Cancer Res. 2007; 13; 844-850.
85. Reincke M, Karl M, Travis WH et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 1994; 78; 790-794.
86. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 1993; 54; 408-410.
87. Varley JM, McGown G, Thorncroft M et al. Are there low-penetrance TP53 alleles? evidence from childhood adrenocortical tumors. Am. J. Hum. Genet. 1999; 65; 995-1006.
88. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J. Natl Cancer Inst. 1994; 86; 1707-1710.
89. Latronico AC, Pinto EM, Domenice S et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 2001; 86; 4970-4973.
90. Schulte KM, Mengel M, Heinze M et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J. Clin. Endocrinol. Metab. 2000; 85; 441-448.
91. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF- binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 1998; 83; 1713-1720.
92. Gicquel C, Bertagna X, Schneid H et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 1994; 78; 1444-1453.
93. Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 1993; 77; 852-858.
94. Gao ZH, Suppola S, Liu J, Heikkila P, Janne J, Voutilainen R. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J. Clin. Endocrinol. Metab. 2002; 87; 1170-1176.
95. Gicquel C, Raffin-Sanson ML, Gaston V et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 1997; 82; 2559-2565.
96. Voutilainen R, Ilvesmaki V, Ariel I, Rachmilewitz J, de Groot N, Hochberg A. Parallel regulation of parentally imprinted H19 and insulin-like growth factor-II genes in cultured human fetal adrenal cells. Endocrinology 1994; 134; 2051-2056.
97. Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin. Endocrinol. (Oxf) 2008; 68; 264-270.
98. Tissier F, Cavard C, Groussin L et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005; 65; 7622-7627.
99. Latronico AC. Role of ACTH receptor in adrenocortical tumor formation. Braz. J. Med. Biol. Res. 2000; 33; 1249-1252.
100. Light K, Jenkins PJ, Weber A et al. Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia? Life Sci. 1995; 56; 1523-1527.
101. Demeure MJ, Doffek KM, Komorowski RA, Gorski J. Gip-2 codon 179 oncogene mutations: absent in adrenal cortical tumors. World J. Surg. 1996; 20; 928-931.
102. Gicquel C, Dib A, Bertagna X, Amselem S, Le Bouc Y. Oncogenic mutations of alpha-Gi2 protein are not determinant for human adrenocortical tumourigenesis. Eur. J. Endocrinol. 1995; 133; 166-172.
103. Laurell C, Velazquez-Fernandez D, Lindsten K et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur. J. Endocrinol. 2009; 161; 141-152.
104. de Reynies A, Assie G, Rickman DS et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009; 27; 1108-1115.
105. Fernandez-Ranvier GG, Weng J, Yeh RF et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch. Surg. 2008; 143; 841-846.
106. Slater EP, Diehl SM, Langer P et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol. 2006; 154; 587-598.
107. Velazquez-Fernandez D, Laurell C, Geli J et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005; 138; 1087-1094.
108. de Fraipont F, El Atifi M, Cherradi N et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 2005; 90; 1819-1829.
109. Giordano TJ, Thomas DG, Kuick R et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003; 162; 521-531.
110. Stephan EA, Chung TH, Grant CS et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Cancer Ther. 2008; 7; 425-431.
111. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of endocrine organs. Lyon: IARC Press, 2004.
112. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch. Pathol. Lab. Med. 2008; 132; 1272-1284.
113. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J. Med. Genet. 2002; 39; 617-622.
114. De Graeff J, Horak BJV. The incidence of pheochromocytoma in The Netherlands. Acta Med. Scand. 1964; 176; 583-593.
115. Beard CM, Carney JA, Sheps SG, Lie JT, Kurland LT. Incidence of phaeochromocytoma. J. Hum. Hypertens. 1989; 3; 481.
116. Oosterwijk JC, Jansen JC, van Schothorst EM et al. First experiences with genetic counselling based on predictive DNA diagnosis in hereditary glomus tumours (paragangliomas). J. Med. Genet. 1996; 33; 379-383.
117. Erickson D, Kudva YC, Ebersold MJ et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J. Clin. Endocrinol. Metab. 2001; 86; 5210-5216.
118. Young WF Jr. Paragangliomas: clinical overview. Ann. N.Y. Acad. Sci. 2006; 1073; 21-29.
119. Machens A, Brauckhoff M, Gimm O, Dralle H. Risk-oriented approach to hereditary adrenal pheochromocytoma. Ann. N.Y. Acad. Sci. 2006; 1073; 417-428.
120. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen's disease and pheochromocytomas. J. Urol. 1999; 162; 1582-1586.
121. Neumann HP, Cybulla M, Shibata H et al. New genetic causes of pheochromocytoma: current concepts and the clinical relevance. Keio J. Med. 2005; 54; 15-21.
122. Dahia PL, Hao K, Rogus J et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res. 2005; 65; 9651-9658.
123. Dahia PL, Ross KN, Wright ME et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005; 1; 72-80.
124. Tischler AS, Kimura N, McNicol AM. Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann. N.Y. Acad. Sci. 2006; 1073; 557-570.
125. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J. Intern. Med. 2009; 266; 19-42.
126. Dannenberg H, Komminoth P, Dinjens WN, Speel EJ, de Krijger RR. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocr. Pathol. 2003; 14; 329-350.
127. Petri BJ, Speel EJ, Korpershoek E et al. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Mod. Pathol. 2008; 21; 407-413.
128. Bender BU, Gutsche M, Glasker S et al. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J. Clin. Endocrinol. Metab. 2000; 85; 4568-4574.
129. Jarbo C, Buckley PG, Piotrowski A et al. Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. Int. J. Cancer 2006; 118; 1159-1164.
130. Edstrom E, Mahlamaki E, Nord B et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am. J. Pathol. 2000; 156; 651-659.
131. Carney A. The triad of gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma. A five year review. Medicine 1983; 62; 159-169.
132. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am. J. Med. Genet. 2002; 108; 132-139.
133. Erlic Z, Neumann HP. When should genetic testing be obtained in a patient with phaeochromocytoma or paraganglioma? Clin. Endocrinol. (Oxf) 2009; 70; 354-357.
134. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Dat. Acta Med. Scand. 1986; 220; 225-232.
135. Hartley L, Perry-Keene D. Phaeochromocytoma in Queensland-1970-83. Aust. NZ J. Surg. 1985; 55; 471-475.
136. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust. NZ J. Med. 2000; 30; 648-652.
137. Bulow B, Jansson S, Juhlin C et al. Adrenal incidentaloma-follow-up results from a Swedish prospective study. Eur. J. Endocrinol. 2006; 154; 419-423.
138. Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzednicka J et al. 1, 111 patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors. Ann. N.Y. Acad. Sci. 2006; 1073; 38-46.
139. Vilar L, Freitas Mda C, Canadas V et al. Adrenal incidentalomas: diagnostic evaluation and long-term follow-up. Endocr. Pract. 2008; 14; 269-278.
140. Kopetschke R, Slisko M, Kilisli A et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur. J. Endocrinol. 2009; 161; 355-361.
141. Page DL, DeLellis RA, Hough AJ. Tumors of the adrenal. Fascicle 23: atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology, 1985.
142. Remine WH, Chong GC, Van Heerden JA, Sheps SG, Harrison E. Current management of pheochromocytoma. Ann. Surg. 1974; 179; 740-748.
143. DeLellis RA, Suchow E, Wolfe HJ. Ultrastructure of nuclear 'inclusions' in pheochromocytoma and paraganglioma. Hum. Pathol. 1980; 11; 205-207.
144. Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases, including unusual histologic features. Hum. Pathol. 1990; 21; 1168-1180.
145. Koch CA, Mauro D, Walther MM et al. Pheochromocytoma in von Hippel-Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr. Pathol. 2002; 13; 17-27.
146. Kimura N, Nakazato Y, Nagura H, Sasano N. Expression of intermediate filaments in neuroendocrine tumors. Arch. Pathol. Lab. Med. 1990; 114; 506-510.
147. Kimura N, Miura Y, Nagatsu I, Nagura H. Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchows Arch. A Pathol. Anat. Histopathol. 1992; 421; 25-32.
148. Meijer WG, Copray SC, Hollema H et al. Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin. Chem. 2003; 49; 586-593.
149. Hayes WS, Davidson AJ, Grimley PM, Hartman DS. Extraadrenal retroperitoneal paraganglioma: clinical, pathologic, and CT findings. Am. J. Roentgenol. 1990; 155; 1247-1250.
150. Sclafani LM, Woodruff JM, Brennan MF. Extraadrenal retroperitoneal paragangliomas: natural history and response to treatment. Surgery 1990; 108; 1124-1129.
151. Labrousse F, Leboutet MJ, Petit B et al. Cytokeratins expression in paragangliomas of the cauda equina. Clin. Neuropathol. 1999; 18; 208-213.
152. Chetty R, Pillay P, Jaichand V. Cytokeratin expression in adrenal phaeochromocytomas and extra-adrenal paragangliomas. J. Clin. Pathol. 1998; 51; 477-478.
153. Parry DM, Li FP, Strong LC et al. Carotid body tumors in humans: genetics and epidemiology. J. Natl Cancer Inst. 1982; 68; 573-578.
154. Zak FG, Lawson W. The paraganglionic chemoreceptor system. Physiology, pathology and clinical medicine. New York: Springer, 1983.
155. Arias-Stella J, Valcarcel J. The human carotid body at high altitudes. Pathol. Microbiol. 1973; 39; 292-297.
156. Davaris P, Petraki K, Arvanitis D, Papacharalammpous N, Morakis A, Zorzos S. Urinary bladder paraganglioma (U.B.P.). Pathol. Res. Pract. 1986; 181; 101-106.
157. Leestma JE, Price EB. Paraganglioma of the urinary bladder. Cancer 1971; 18; 1063-1073.
158. Timmers H, Gimenez-Roqueplo AP, Mannelli M, Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr. Relat. Cancer 2009; 16; 391-400.
159. Medeiros LJ, Wolf BC, Balogh K, Federman M. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum. Pathol. 1985; 16; 580-589.
160. Bezuglova TV. Criteria for predicting the outcome of pheochromocytoma by the immunohistochemical and electron microscopic findings. Bull. Exp. Biol. Med. 2003; 136; 408-410.
161. Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch. Pathol. Lab. Med. 1991; 115; 484-487.
162. Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in pheochromocytoma. Hum. Pathol. 1998; 29; 522-526.
163. van der Harst E, Bruining HA, Jaap Bonjer H et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J. Pathol. 2000; 191; 175-180.
164. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol. 2002; 26; 551-566.
165. Strong VE, Kennedy T, Al-Ahmadie H et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 2008; 143; 759-768.
166. Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr. Pathol. 2005; 16; 23-32.
167. August C, August K, Schroeder S et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod. Pathol. 2004; 17; 1119-1128.
168. Eisenhofer G, Bornstein SR, Brouwers FM et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat. Cancer. 2004; 11; 423-436.
169. Portela-Gomes GM, Stridsberg M, Grimelius L, Falkmer UG, Falkmer S. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies. APMIS 2004; 112; 663-673.
170. de Krijger RR, van Nederveen FH, Korpershoek E, Dinjens WN. New developments in the detection of the clinical behavior of pheochromocytomas and paragangliomas. Endocr. Pathol. 2006; 17; 137-141.
171. Waldmann J, Langer P, Habbe N et al. Mutations and polymorphisms in the SDHB, SDHD, VHL, and RET genes in sporadic and familial pheochromocytomas. Endocrine 2009; 35; 347-355.
172. Anouar Y, Yon L, Guillemot J et al. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches. Ann. N.Y. Acad. Sci. 2006; 1073; 533-540.
173. Brouwers FM, Elkahloun AG, Munson PJ et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann. N.Y. Acad. Sci. 2006; 1073; 541-556.
174. Dahia PL. Evolving concepts in pheochromocytoma and paraganglioma. Curr. Opin. Oncol. 2006; 18; 1-8.
175. Suh I, Shibru D, Eisenhofer G et al. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. Ann. Surg. 2009; 250; 983-990.